CAPTRUST Financial Advisors’s Kura Oncology KURA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	36,700 +12,215	+50%	+$115K	﹤0.01%	2332
2026 Q1	$199K	Sell	24,485 -6,930	-22%	-$59.5K	﹤0.01%	2688
2025 Q4	$326K	Buy	31,415 +9,323	+42%	+$97.8K	﹤0.01%	2185
2025 Q3	$196K	Buy	+22,092	New	+$157K	﹤0.01%	2437
2022 Q3	–	Sell	-131	Closed	-$2K	–	3132
2022 Q2	$2K	Hold	131	–	–	﹤0.01%	4479
2022 Q1	$2K	Buy	131 +103	+368%	+$1.49K	﹤0.01%	4500
2021 Q4	$0	Sell	28 -20	-42%	-$324	﹤0.01%	4841
2021 Q3	$1K	Buy	48 +22	+85%	+$415	﹤0.01%	4441
2021 Q2	$1K	Buy	+26	New	+$645	﹤0.01%	4348

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

CAPTRUST Financial Advisors's KURA Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Kura Oncology (KURA) stake by 50% in Q2 2026, buying an estimated $115K and bringing the position to 36,700 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

CAPTRUST Financial Advisors first reported a position in KURA in Q2 2021 and has held it in 9 quarters since. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

CAPTRUST Financial Advisors held 36,700 shares of Kura Oncology worth $403K as of Q2 2026.
CAPTRUST Financial Advisors bought 12,215 Kura Oncology shares in Q2 2026, an estimated $115K.
Kura Oncology made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2332 holding.
CAPTRUST Financial Advisors first reported a position in Kura Oncology in Q2 2021 and has held it in 9 quarters since.
221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.